Stephan Maus

[89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis

A. Schaefer-Schuler, M. Bartholomä, R. Marlowe, 2024, Cancer imaging : the official publication of the International Cancer Imaging Society.

From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer

S. Salah, A. Al-Ibraheem, Baha’ Sharaf, 2024, Cancers.

Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival

A. Schaefer-Schuler, M. Hoffmann, F. Rosar, 2024, Cancers.

225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy

A. Schaefer-Schuler, M. Bartholomä, F. Rosar, 2024, Clinical nuclear medicine.

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT

A. Schaefer-Schuler, M. Bartholomä, R. Marlowe, 2024, Scientific reports.